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ImplementationBackground: Rotavirus (RV) is a major agent of gastroenteritis and an important cause of child death
worldwide. Immunization (RVI) has been available since 2006, and the Federation of International
Societies of Gastroenterology Hepatology and Nutrition (FISPGHAN) identified RVI as a top priority for
the control of diarrheal illness. A FISPGHAN working group on acute diarrhea aimed at estimating the cur-
rent RVI coverage worldwide and identifying barriers to implementation at local level.
Methods: A survey was distributed to national experts in infectious diseases and health-care authorities
(March 2015–April 2016), collecting information on local recommendations, costs and perception of bar-
riers for implementation.
Results: Forty-nine of the 79 contacted countries (62% response rate) provided a complete analyzable
data. RVI was recommended in 27/49 countries (55%). Although five countries have recommended RVI
since 2006, a large number (16, 33%) included RVI in a National Immunization Schedule between 2012
and 2014. The costs of vaccination are covered by the government (39%), by the GAVI Alliance (10%) or
public and private insurance (8%) in some countries. However, in most cases, immunization is paid by
families (43%).
Elevated cost of vaccine (49%) is the main barrier for implementation of RVI. High costs of vaccination
(rs = 0.39, p = 0.02) and coverage of expenses by families (rs = 0.5, p = 0.002) significantly correlate with
a lower immunization rate. Limited perception of RV illness severity by the families (47%), public-health
authorities (37%) or physicians (24%) and the timing of administration (16%) are further major barriers to
large- scale RVI programs.
Conclusions: After 10 years since its introduction, the implementation of RVI is still unacceptably low and
should remain a major target for global public health. Barriers to implementation vary according to set-
ting. Nevertheless, public health authorities should promote education for caregivers and health-care
providers and interact with local health authorities in order to implement RVI.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
Rotavirus (RV) is the most common agent of acute
gastroenteritis (AGE) in children under five years of age, and the
1638 A. Lo Vecchio et al. / Vaccine 35 (2017) 1637–1644most severe independent of age [1,2]. Despite a progressive
decrease in diarrhea-related deaths, RV is still a major cause of
mortality mainly in developing countries [3]. RV disease can be
prevented by vaccination, and 95% of RV-induced deaths occurred
in 72 countries, which were all eligible to receive GAVI Alliance
support. As of January 1, 2016, 80 of the 193 countries worldwide
have introduced RV vaccines in their National Immunization Pro-
grams (NIP) [4]. Although there are public health barriers to the
implementation of RV immunization (RVI), WHO and other author-
ities recommend universal immunization and considered it a prior-
ity in countries with high rotavirus gastroenteritis-associated
fatality rates, such as in south and south-eastern Asia and sub-
Saharan [5]. Two oral vaccines with high efficacy and good safety
profiles are currently available: RotarixTM administered in a 2-
dose schedule, and RotaTeq administered in a 3-dose schedule.
Both vaccines aim to prime broad immune responses followed by
progressively broader protection developing through successive
natural rotavirus infections [6–9].
Thus far, RV vaccines have been introduced in United States,
some European countries, and Australia and are being imple-
mented in selected countries in Asia.
Limited time frame (six to eight weeks following birth) for
administration was considered a potential barrier to large-scale
immunization. Therefore, even if early immunization is still
favored, WHO loosened its recommendation and allowed infants
to receive RV vaccine (either RotaTeq or RotarixTM) together with
DTP [5].
The likelihood of intussusception following RVI is low based on
the results of both large clinical trials and post-marketing surveil-
lance data. Furthermore, the benefit in lives saved by broadening
age restrictions for immunization may well exceed the risk of
potential deaths related to intussusception [10].
In 2012, the Federation of International Societies of Pediatric
Gastroenterology, Hepatology, and Nutrition (FISPGHAN) identi-
fied the spread of RV vaccination as a top priority for the control
of diarrheal illness in childhood [11].
In order to estimate current RVI coverage and identify the major
barriers to local implementation, the FISPGHAN Working Group
(WG) on AGE conducted a global survey aimed at collecting infor-
mation on RVI worldwide.
2. Methods
2.1. Working group and survey
The WG on AGE was created during the FISPGHAN World Con-
gress held in Taiwan in 2012 and encompasses two experts of each
continental Society of Pediatric Gastroenterology, Hepatology and
Nutrition: European (ESPGHAN), Asian Pan Pacific (APPSGHAN),
Commonwealth Association (CAPGHAN), Latin American (LASP-
GHAN) and North American (NASPGHAN) Societies.
In order to identify and promote practical interventions that
will help to reduce the burden of AGE in children worldwide, the
WG on AGE collaborated with experts in the field of RVI actively
involved in the dissemination of RVI around the world.
The WG coordinators developed a survey including information
on the availability of RV vaccines, inclusion in the NIP, immuniza-
tion coverage according to local available data, costs and financial
support, main perceived barriers to implementation, possible
interventions to achieve >90% global coverage (see Supplemental
material).
2.2. Study design
National experts in infectious diseases and vaccination from
several countries in the world were contacted between October2015 and May 2016. Experts were identified among the members
of national institutes for health, panels for local immunization pro-
grams, scientific societies working and/or reporting data on RVI
(see Supplemental material).
All of them were asked to fill-in a survey to give information on
inclusion of RV vaccination in their country’s NIP, implementation
programs, costs and their perception of local barriers to implemen-
tation. All participants were encouraged to provide original local
evidence supporting their data and to report the source of informa-
tion (see Supplemental material).
2.3. Data analysis
The WG planned to reach at least one referral expert for each
world country. When more than one expert from the same country
participated to the survey, the data were discussed and combined
and analyzed as a single source.
Since data and opinions about local barriers may vary slightly
according to the setting, rough data were analyzed and reported
according to the Human Development Index (HDI) list of countries
with advanced economy (http://hdr.undp.org/en/content/human-
development-index-hdi) and countries were differentiated into
high HDI countries, medium HDI countries and low HDI countries.
Data were summarized as means ± SD for continuous variables
and as percentage and frequencies for categorical variables. Com-
parison of groups was performed using one-way analysis of vari-
ance (ANOVA) for multiple group comparisons. Chi-square test
with Fisher’s correction was used to address any differences for
categorical variables, as needed. A p value of 0.05 or less was con-
sidered as significant. Results were updated in December 2015.3. Results
Ninety-one experts in the field were contacted by e-mail or met
personally at medical meetings, symposia and workshops world-
wide. Among the 79 countries contacted, 49 provided a survey eli-
gible for analysis (response rate 62%) (Fig. 1). Forty-two of the 49
responders provided data for all required fields, but for other seven
countries the data on RVI coverage were not available (Ireland,
Lithuania, Portugal, Romania, Singapore, Slovenia, Switzerland)
although the survey was completed in all other fields.
Responders were equally distributed between low- (23, 47%)
and medium/high-income countries (26, 53%).
3.1. Rotavirus immunization coverage and costs
RVI was recommended in 27 out of the 49 countries (55%) par-
ticipating in the global survey (eTable 3). Although some countries
have recommended RVI since 2006, most countries (16/49, 33.3%)
first included RVI in the NIP between 2012 and 2014 (eTable 3). RVI
rates showed a scattered pattern from 0 to over 90% according to
different countries. Overall RVI coverage is reported in Fig. 2.
RotarixTM and Rotateq are both distributed worldwide, with 40
(81.6%) and 38 (77.5%) countries respectively, but Rotarix
resulted to be prevalent in African countries (Table 1).
The costs of vaccines are substantially different, being higher in
European and American and lower in Asian and African countries
(Table 2). Costs reported for a complete vaccination cycle with
Rotateq were slightly higher than those of RotarixTM in average
(176.8 vs 103.8USD, p = 0.14). In most countries these costs were
charged directly to families (42.8%) (Table 2). In other nations
the costs are covered by the government (38.7%), by international
organization such as the GAVI Alliance (10.2%) or public and pri-
vate insurance (8.1%). However, in the countries in which financial
support by public authorities is limited or related to by family
Fig. 1. Flowchart of study methodology. FISPGHAN: Federation of International
Societies of Pediatric Gastroenterology Hepatology and Nutrition, APPSGHAN: Asian
Pan Pacific Society of Pediatric Gastroenterology Hepatology and Nutrition,
CAPGHAN: Commonwealth Association of Paediatric Gastroenterology & Nutrition,
ESPGHAN: European Society of Pediatric Gastroenterology Hepatology and Nutri-
tion, LASPGHAN: Latin American Society of Pediatric Gastroenterology Hepatology
and Nutrition, NASPGHAN: North American Society of Pediatric Gastroenterology
Hepatology and Nutrition. CDC: Center for Disease Control and Prevention – Atlanta
United States.
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location, it’s possible for families to obtain one or both vaccines
in the private sector. Anyway, uptake is usually substantially less
in the private than in the public sector.
It should be noted that national policies for reimbursement are
often reassessed. For example, in Latvia, Europe, the governmentFig. 2. Global coverage for Rotavirus Immunization: ehas partially reimbursed RV vaccination since September 2012
and full reimbursement was introduced in January 2015. In France
the vaccination was available since 2006 and has been successively
included in the NIP in 2013 at expenses of families. However, due
to a safety warning released by the National Agency of Drug Safety,
at the moment the survey is collected, French government was
reviewing RVI recommendations and reimbursement. In the Uni-
ted States of America, beginning September 2010, children 0
through 18 years that are enrolled in new private health plans
are eligible to receive vaccines (including RV). Children covered
by government insurance were already fully eligible.
These major changes in local policy for RVI may well signifi-
cantly impact future immunization coverage.3.2. Barriers to local implementation
The direct and indirect costs for immunization and the limited
perception of RV severity by the families are two major barriers
for large-scale implementation of RVI programs (Fig. 3, eTable 4).
High costs of vaccination (rs = -0.39, p = 0.02) and its charge to
families (rs = 0.5, p = 0.002) significantly correlate with a lower
immunization rate (Fig. 4). Only eight countries reported the tim-
ing of first administration as a potential barrier (eTable 4).
The underestimation of RV severity by public health authorities
is a common barrier worldwide, however, it is particularly relevant
in developing countries with low and medium HDI (eTable 4).
An impact of anti-vaccination movements and a general fear
about vaccines’ side effects was reported in the United States, Lat-
via, and Iraq. In France, the notification of serious side effects after
RVI had a relevant impact on national agency recommendations
and on local immunization coverage.
In Malaysia, the government did not consider RVI as a health
priority and restricted funds for RVI implementation and reim-
bursement. In addition, two experts reported that the finding of
porcine circovirus DNA fragments in vaccines available on the mar-
ket [12,13] had a relevant negative impact on local implementation
of RV vaccines for religious reasons.
In Zambia, the overall erratic distribution of vaccines has been
reported as a major barrier to large-scale implementation of RVI.stimate 2015** (data collected up to May 2016).
Table 1
Inclusion of Rotavirus Immunization in national immunization plans according to
different countries.
Continent Country Recommendation
by national
immunization plan
Year of start
Africa Botswana Recommended 2012
Ethiopia Recommended 2013
Ghana Recommended 2012
Kenya Recommended 2014
Nigeria Not recommended
Rwanda Recommended 2012
Senegal Recommended 2014
Tanzania Recommended 2012
Uganda Not recommended
Zambia Recommended 2013
Asia and Oceania Bangladesh Not recommended
Cambodia Not recommended
China Not recommended
Japan Recommendeda 2011
India Recommendeda 2016
Indonesia Not recommended
Iraq Recommended 2012
Israel Recommended 2011
Malaysia Not recommended
Singapore Not recommended
South Korea Not recommended
Taiwan Recommended 2006
Thailand Not recommended
Europe Austria Recommended 2007
Belgium Recommended 2006
Estonia Recommended 2014
Finland Recommended 2009
France Recommended 2013
Germany Recommended 2013
Ireland Not recommended
Italy Not recommended
Latvia Recommended 2010
Lithuania Not recommended
Netherlands Not recommended
Norway Recommended 2014
Poland Not recommended
Portugal Not recommended
Romania Not recommended
Russia Not recommended
Slovenia Not recommended
Switzerland Not recommended
Turkey Not recommended
United Kingdom Recommended 2013
North America Canada Recommendeda 2006
Mexico Recommended 2013
USA Recommended 2006
South America Brazil Recommended 2006
Chile Not recommended
Peru Recommended 2009
a RV vaccination is recommended only in some regions of the country.
1640 A. Lo Vecchio et al. / Vaccine 35 (2017) 1637–16443.3. Role of Scientific Societies and Health-care authorities
To the question ‘‘How could Scientific Societies and Health-care
authorities help to achieve the goal?” most experts suggested edu-
cational initiatives to be adopted as primary intervention (Fig. 5).
The majority of responders identified the need of public educa-
tional campaigns (33/49, 67.3%) or educational programs
addressed to local health-care providers (24/49, 48.9%).
This is particularly true in low-income countries where the
majority of responders indicated the education directed to care-
givers (88%) or physicians (50%) as the major interventions to be
promoted (Fig. 5). According to the result of our survey, the educa-
tion programs for caregivers could be started in the third trimester
of gestation or alternatively during first well-baby visits. The lattermay also provide an optimal opportunity to administer the
vaccine.
Countries with medium-high or very high income suggested to
provide support for public health legislation aiming to reduce vac-
cination costs and simplify access to vaccination (Fig. 5). In addi-
tion, scientific societies should interact with national health
authorities to promote the inclusion of RVI in the NIP and to
enhance the cooperation amongst the active stakeholders to
improve the spread of information.4. Discussion
This study provides a worldwide overview of the status of RVI
and outlines the main barriers to local implementation of RV vac-
cination with the final aim of identifying possible interventions
that may help to reach a goal of global coverage. Our results
showed that common barriers to the implementation of RV vaccine
included its costs and the perception of a low disease burden as
observed in a previous publication in European countries where
potential safety concerns represented a third relevant barrier[14].4.1. RVI coverage and costs
Oral RV vaccines can prevent severe cases of infection. Even if
RV vaccination is currently recommended by WHO and all author-
itative guidelines [5,15–19], RVI coverage significantly varies in the
world, and even within the same geographical area (from 0 to over
90%). In Europe only few countries such as Austria, Belgium and
Finland have reached adequate vaccination coverage as high as
90%, despite the specific recommendations of European guidelines
since 2008 [18]. The inclusion in those countries of the RV vaccine
in the NIP since 2006–2007 and the implementation of clinical
studies conducted by local researchers [20–22] may well have pos-
itively impacted the current rate of immunization coverage.
The scenario in North and South America seems to be different:
in almost all countries included in the survey the vaccine is recom-
mended and the coverage rates range from 50% (Peru) to over 90%
(United States). The only exception is represented by Canada,
where recommendations vary according to regional provinces
and coverage has been estimated <10%. Coverage in Asian coun-
tries is even lower and only Japan reported values above 10%, prob-
ably because in most Asian countries the RV vaccine is not
nationally recommended by health authorities, with exception of
Taiwan and Iraq, and more recently India.
High coverage rates have been reached in African countries
where GAVI alliance supported RV vaccination campaign (Rwanda,
Ghana, Tanzania and Botswana).
In addition, we observed that, after approval of the two RV vac-
cines and early endorsement by some countries in 2006, most
countries recommended RVI very recently between 2012 and
2014. This two-peak distribution might be affected by the emer-
gence of data on potential side effects, including the risk of intesti-
nal intussusception (2008–2012) [23] and the presence of porcine
circovirus in RotarixTM (2009–2010) [24].
According to our results there was no significant difference in
the distribution of the two main types of vaccines among the par-
ticipating countries. However RotaTeq tended to be less
employed in African countries confirming previous reports that
identified RotarixTM as a preferred choice due to a better cost-
effectiveness, the requirement of fewer doses, less storage space,
and proven thermo-stability [25]. For similar reasons, the GAVI
Alliance subsidizes much more 2-dose rather than 3-dose RV vac-
cine. Significant differences emerged in relation to costs, which are
higher in European and American countries and lower in Asia and
Africa. This represents a commitment that developed countries
Table 2
Rotavirus vaccines and relative costs according to continents.
Questions Total (n = 49) Africa (n = 10) Asia (n = 13) Europe (n = 20) North America (n = 3) South America (n = 3) p
Inclusion in NIS (n, %) 27 (55.1) 8 (80) 5 (38.4)b 9 (45)b 3 (100) 2 (66.6) 0.116
Available vaccine
Rotarix (n, %) 40 (81.6) 7 (70) 10 (76.9) 17 (85) 3 (100) 3 (100) 0.627
RotaTeq (n, %) 38 (77.5) 3 (30) 11 (84.6) 18 (90) 3 (100) 3 (100) 0.002
Other (n, %) 2 (4) 0 (0) 2 (15.3) 0 (0) 0 (0) 0 (0) 0.217
None (n, %) 3 (6.1) 1 (10) 2 (18.2) 0 (0) 0 (0) 0 (0) 0.422
Costs in USD
Rotarix (mean + SD) 103.8 (701) 12.6 (185) 80 (56.1) 140.6 (56.4) 182 (45.3) 575 (61.5) <0.001
RotaTeq (mean + SD) 176.8 (2674) 15 (NA) 84.9 (478) 253.2 (3633) 187.8 (534) 125.5 (44.5) 0.64
Other (mean + SD) 37.5 (488) – 37.5 (48.8) – – – NA
Payment charged to:
Family (n, %) 21 (42.8) 2 (20) 8 (61.5) 10 (50) 0 (0)a 1 (33.3) 0.149
Government (n, %) 19 (38.7) 4 (40) 3 (23) 7 (35) 3 (100) 2 (66.6) 0.054
GAVI Alliance (n, %) 5 (10.2) 4 (40) 1 (7.6) 0 (0) 0 (0)a 0 (0) 0.014
Insurance (n, %) 4 (8.1) 0 (0) 1 (9) 3 (15) 0 (0)a 0 (0) 0.638
No answer 1 (2.0) 0 (0) 1 (9) 0 (0) 0 (0) 0 (0) NA
NIS = National Immunization Schedule, NA = Not assessable.
a Private Insurance may cover the cost of vaccination.
b One country changed recommendation in 2015–2016 (see text).
Fig. 3. Barriers to local implementation of Rotavirus immunization (Pareto Chart).
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national support [26]. As of mid-2016, GAVI supported the intro-
duction of RVI in the NIP of 43 African and South American
countries [26].
4.2. Barriers to RVI implementation
Elevated costs of immunization and a misperception regarding
the potential severity of RV infection and its consequences havebeen identified as the major barriers to universal dissemination
of RVI. However, the factors limiting local implementation vary
greatly between countries and even within the same geographic
area. In Europe, the opinion of experts varied country by country,
from Finland where no barriers to implementation were reported
to Slovenia where RVI ‘‘is not recognized by far as a priority among
vaccine-preventable diseases”. Awareness of disease burden can
drive vaccination uptake, as suggested in several studies
[14,27,28]. According to our results it was felt that a large percent-
Fig. 4. Correlation between Rotavirus immunization rate and its coverage expenses.
Fig. 5. Activities to improve rates of Rotavirus immunization coverage.
1642 A. Lo Vecchio et al. / Vaccine 35 (2017) 1637–1644age of caregivers are simply not aware of risks of RV infection prob-
ably because they received inadequate information. Many parents
are aware of the risk of hospitalization or death, but most do not
know about the advantages and availability of RV vaccines in their
own country. Counseling can be an integral part of health educa-
tion to the public and can provide useful information against
vaccine-preventable diseases to families who accept to receive
information by health-care personnel [27].
Unfavorable cost-effectiveness has been put forward as a
reason not to implement universal RV vaccination in severalHDI-countries [28]. Since in HDI countries the RV infection is
managed with high efficacy, the ratio between admission and sick
children is low. In addition, either health-related costs and social
costs (working day loss) are underscored and, as a consequence,
health authorities consider RVI expensive [29].
Universal vaccination has been estimated to be cost-effective
from a wider societal perspective, in particular in relation to the
beneficial effects coming from herd immunity [30]. In keeping with
our results, previous studies also identified the concerns about
reimbursement issues and parental acceptance of the vaccine as
A. Lo Vecchio et al. / Vaccine 35 (2017) 1637–1644 1643major barriers to optimal implementation of RV vaccination.
Copayment systems or funding by sickness funds have been imple-
mented as an alternative to national funding in several high-
income and medium-income countries [14]. However, guidelines
were against the hypothesis of immunizing at risk populations
only [18,19].
A further barrier is represented by the overall concern of
vaccine-related side effects that, together with anti-vaccination
movements, impact on immunization campaign worldwide. In
France, the notification in December 2014 of three deaths and
about 50 intussusceptions after RV vaccine administration signifi-
cantly changed government’s attitude towards routine RVI and
national agency recommendations (letter reported at http://
www.bmj.com/content/350/bmj.h2867/rr-1).
Historically the time of administration of RV vaccine was seen
as a barrier. According to our results this seems to be a minor issue,
also because WHO changed its recommendation in 2013, introduc-
ing the first vaccination dose together with DTP vaccination start-
ing from the second month of life. This intervention could enhance
RVI and reach children who were previously excluded from the
benefits of RVI.
Other barriers have been reported by experts as a result of the
direct interaction that FISPGHAN had with local experts: one of
these is related to a religious matter. In Malaysia, a country with
a predominance of people practicing Islam (over 60%), the finding
of DNA fragments of porcine circoviruses type-1 in RV vaccines
RotarixTM has been reported as a relevant barrier for local imple-
mentation of large-scale immunization programs.
The Strategic Advisory Group of Experts on immunization in
2010 reported to the World Health Organization that porcine cir-
covirus type-1 is not known to cause disease in humans and is
often found in food products, confirming the safety of RotarixTM
[5,24]. However, according to our data, in an Islamic-prevalent
country the potential assumption of pig derivate seems to over-
weigh safety reasons and this significantly impacts on regional
health authorities, religious leaders and families’ beliefs.
4.3. Future prospective for RVI implementation
Educational initiatives directed at health-care providers and
caregivers have been identified as primary interventions that
should be adopted and promoted. However the role of FISPGHAN
is likely to vary according to setting and countries needs. Countries
with medium-high or very-high income asked scientific societies
to support public health legislation aimed at a reduction in vacci-
nation costs and simplified access to vaccination. Systems involv-
ing different health-care workers were effective. For example, in
Norway the nurses, who are responsible for the child immuniza-
tion program, provide information to caregivers using printed
information material and web-pages. In developing areas, some
experts suggested a role by scientific societies (including FIPS-
GHAN) in supporting public health legislation and the introduction
of RVI in NIP as well as in promoting the enhancement of cooper-
ation and information flow between local health-care practitioners,
regulatory authorities and field workers. More recently National
Immunization Technical Advisory Groups (NITAGs) have been
established in the majority of countries to advise Ministries of
Health on the value of new vaccines and to develop strategies
through the analysis and discussion of scientific evidence [30]. By
the end of 2012, half of the countries in the world reported the
existence of a NITAG with a formal legislative or administrative
basis (with a high of 86% in the Eastern Mediterranean Region)
[31].
This survey was supposed to cover as many countries as possi-
ble to ensure a better view of RVI scenario in the world. Unfortu-
nately, despite our commitment and efforts, we have been ableto obtain reliable information from only a quarter of world coun-
tries, and this represents a limitation of our study. However, we
observed a balanced distribution between high- and low-income
countries and provided useful new information about RVI coverage
and barriers to implementation of RVI. A further limitation of our
survey is that data about RVI coverage are based on single person
reports. However it should be considered that all enrolled health-
care workers are experts in the field and provided supporting data
including material from local literature, websites or published
material (see Online-only material).
In conclusion, immunization is the best approach for preventing
RV infection [3,5]
After approximately 10 years since the introduction of RVI, the
implementation of this major life saving intervention is still unac-
ceptably low and remains a major target for reaching the Millen-
nium Developmental Goal.
Barriers to implementation vary according to setting and local
conditions, but the costs of RVI programs and perceptions about
disease burden are major barriers for global dissemination of RVI.
In order to sustain and implement RVI, medical professional soci-
eties and public health authorities should promote education for
caregivers and physicians and interact with local health organiza-
tions to enhance networking among stakeholders and develop
strategies to reduce RVI-related costs.Declaration of interests
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